Evaluation of fractalkine (FKN) and secreted frizzled-related protein 4 (SFRP-4) serum levels in patients with prediabetes and type 2 diabetes

Basit Öğe Kaydı
dc.contributor.authorBaldane, S.
dc.contributor.authorİpekci, S. H.
dc.contributor.authorEkin, A.
dc.contributor.authorAbuşoğlu, Sedat
dc.contributor.authorÜnlü, Ali
dc.contributor.authorKebapcılar, Levent
dc.date.accessioned2020-03-26T19:53:49Z
dc.date.available2020-03-26T19:53:49Z
dc.date.issued2018
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVE: The objective of this study is to compare serum levels of FKN and SFRP-4 in patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes mellitus (T2DM). METHODS: A total of 152 patients presented to the endocrinology outpatient clinic of our hospital were included in the study. Eighty-two patients with a history of T2DM were assigned to the T2DM group. IGT (n = 34) and NGT (n = 36) groups included the patients who received oral glucose tolerance test outcomes. RESULTS: Serum FKN levels were significantly higher in the IGT and T2DM groups compared to the NGT group (p < 0.001 and p < 0.001, respectively). Serum SFRP-4 levels were significantly higher in the T2DM group compared to the IGT and NGT groups (p = 0.001 and p = 0.004, respectively). A significant correlation was observed between FKN and fasting glucose levels. SFRP-4 was significantly correlated with fasting glucose, HbA1c, and triglyceride levels. CONCLUSION: To our knowledge, increased FKN levels in patients with IGT were demonstrated for the first time in this study. The results of our study support the opinion that FKN and SFRP-4 may contribute to the pathogenesis of T2DM.en_US
dc.description.sponsorshipSelcuk UniversitySelcuk University [BAP 15401081]en_US
dc.description.sponsorshipThis study has been partially supported by Selcuk University under grant number BAP 15401081.en_US
dc.identifier.doi10.4149/BLL_2018_021en_US
dc.identifier.endpage115en_US
dc.identifier.issn0006-9248en_US
dc.identifier.issn1336-0345en_US
dc.identifier.issue2en_US
dc.identifier.pmid29455547en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage112en_US
dc.identifier.urihttps://dx.doi.org/10.4149/BLL_2018_021
dc.identifier.urihttps://hdl.handle.net/20.500.12395/36600
dc.identifier.volume119en_US
dc.identifier.wosWOS:000425183100009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCOMENIUS UNIVen_US
dc.relation.ispartofBRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectinflammationen_US
dc.subjectinsulin secretionen_US
dc.subjectsecreted frizzled-related protein 4en_US
dc.subjectfractalkineen_US
dc.titleEvaluation of fractalkine (FKN) and secreted frizzled-related protein 4 (SFRP-4) serum levels in patients with prediabetes and type 2 diabetesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu